Literature DB >> 12827047

Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation.

E J Dudenhoefer1, M Nouri, I K Gipson, K H Baratz, A S Tisdale, T P Dryja, J C Abad, C H Dohlman.   

Abstract

PURPOSE: To compare the histopathology of three PMMA collar button type keratoprosthesis (KPro)/corneal specimens, explanted due to various complications, with that from one KPro/corneal specimen taken postmortem from an otherwise "healthy" enucleated eye.
METHODS: Patient 1 (chemical injury) had no problems for 3 years after KPro placement; the entire eye was obtained postmortem. Patient 2 (repeated graft failures, nonautoimmune disease) developed an "unlaserable" retroprosthesis membrane 4 months after KPro placement. A new KPro was placed. Patient 3 [ocular cicatricial pemphigoid (OCP)] developed tissue melt at the KPro-cornea interface 7 months after KPro placement, and the KPro was replaced. Patient 4 (OCP) developed progressive corneal melt around the KPro 3.5 years after placement resulting in replacement. All KPro/cornea specimens were processed and sectioned for histology with the KPro in place.
RESULTS: All patients exhibited growth of corneal or conjunctival derived epithelium under the KPro front plate. In patients 1 and 2, no epithelial downgrowth was noted and the keratocyte density appeared normal with few inflammatory cells present. Dense fibrous tissue was present behind the KPro in patient 2. Patients 3 and 4 showed massive inflammatory cell infiltration and tissue necrosis with "melt" adjacent to the stem resulting in epithelial downgrowth.
CONCLUSIONS: Corneal inflammation and degradation after KPro placement correlate well with the preoperative diagnostic category. Patients with immune-related corneal surface disease can exhibit marked inflammatory responses leading to necrosis, stromal melting, and the formation of an epithelial fistula. In contrast, patients without autoimmune corneal disease demonstrate a remarkably noninflamed cornea with intact keratocytes and without epithelial ingrowth, commensurate with their clinical appearance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827047     DOI: 10.1097/00003226-200307000-00007

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Microkeratome assisted deep lamellar keratoprosthesis.

Authors:  S Shimmura; H Miyashita; Y Uchino; T Taguchi; H Kobayashi; J Shimazaki; J Tanaka; K Tsubota
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

2.  Five year follow up of biocolonisable microporous fluorocarbon haptic (BIOKOP) keratoprosthesis implantation in patients with high risk of corneal graft failure.

Authors:  J L Alió; M E Mulet; H Haroun; J Merayo; J M Ruiz Moreno
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

3.  High-resolution spectral domain anterior segment optical coherence tomography in type 1 Boston keratoprosthesis.

Authors:  Brett L Shapiro; Dennis E Cortés; Eric K Chin; Jennifer Y Li; John S Werner; Ellen Redenbo; Mark J Mannis
Journal:  Cornea       Date:  2013-07       Impact factor: 2.651

4.  The Boston Keratoprosthesis: comparing corneal epithelial cell compatibility with titanium and PMMA.

Authors:  Jared D Ament; Sandra J Spurr-Michaud; Claes H Dohlman; Ilene K Gipson
Journal:  Cornea       Date:  2009-08       Impact factor: 2.651

5.  Short-term visual outcomes of Boston keratoprosthesis type I in saudi arabia.

Authors:  Khalid Al Arfaj; Mohamed Hantera
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

6.  In vivo evaluation of a novel scaffold for artificial corneas prepared by using ultrahigh hydrostatic pressure to decellularize porcine corneas.

Authors:  Shuji Sasaki; Seiichi Funamoto; Yoshihide Hashimoto; Tsuyoshi Kimura; Takako Honda; Shinya Hattori; Hisatoshi Kobayashi; Akio Kishida; Manabu Mochizuki
Journal:  Mol Vis       Date:  2009-10-13       Impact factor: 2.367

Review 7.  Boston keratoprosthesis - Clinical outcomes with wider geographic use and expanding indications - A systematic review.

Authors:  Khalid Al Arfaj
Journal:  Saudi J Ophthalmol       Date:  2015-02-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.